Trial Profile

Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping With Suppressed Viremia (GUSTA): a Multicenter, Open-label, Randomized Controlled Trial

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir (Primary) ; Maraviroc (Primary) ; Antiretrovirals; Ritonavir
Indications HIV infections
Focus Therapeutic Use
Acronyms GUSTA

Most Recent Events

27 Oct 2017 Results of substudy assessing immune activation/inflammation and microbial translocation presented at the 16th European AIDS Conference
05 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
03 Feb 2015 Planned End Date changed from 1 May 2016 to 1 May 2017, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com